Last reviewed · How we verify
Sumatriptan Succinate Oral Tablet
Sumatriptan selectively binds to serotonin 5-HT1B/1D receptors on cranial blood vessels and nerve terminals, causing vasoconstriction and inhibiting neuropeptide release to relieve migraine headaches.
Sumatriptan selectively binds to serotonin 5-HT1B/1D receptors on cranial blood vessels and nerve terminals, causing vasoconstriction and inhibiting neuropeptide release to relieve migraine headaches. Used for Acute treatment of migraine with or without aura in adults.
At a glance
| Generic name | Sumatriptan Succinate Oral Tablet |
|---|---|
| Also known as | Sumigran tablets |
| Sponsor | Damanhour Teaching Hospital |
| Drug class | Triptan (5-HT1B/1D receptor agonist) |
| Target | 5-HT1B receptor, 5-HT1D receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Sumatriptan is a selective serotonin 5-HT1B/1D receptor agonist that works through two primary mechanisms: it causes constriction of dilated cranial blood vessels implicated in migraine pathophysiology, and it inhibits the release of vasoactive neuropeptides from trigeminal nerve terminals. This dual action rapidly terminates the migraine attack and associated symptoms including pain, nausea, and photosensitivity.
Approved indications
- Acute treatment of migraine with or without aura in adults
Common side effects
- Chest pain or pressure
- Dizziness
- Drowsiness
- Tingling or numbness
- Flushing
- Nausea
- Warm sensation
Key clinical trials
- Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002) (PHASE1)
- Is Theophylline More Effective Than Sumatriptan in the Treatment of Post-dural Puncture Headache (PHASE4)
- Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults (PHASE1)
- Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex® (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sumatriptan Succinate Oral Tablet CI brief — competitive landscape report
- Sumatriptan Succinate Oral Tablet updates RSS · CI watch RSS
- Damanhour Teaching Hospital portfolio CI